Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31754
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOssenkoppele, Rik-
dc.contributor.authorPichet Binette, Alexa-
dc.contributor.authorGroot, Colin-
dc.contributor.authorSmith, Ruben-
dc.contributor.authorStrandberg, Olof-
dc.contributor.authorPalmqvist, Sebastian-
dc.contributor.authorStomrud, Erik-
dc.contributor.authorTideman, Pontus-
dc.contributor.authorOhlsson, Tomas-
dc.contributor.authorJögi, Jonas-
dc.contributor.authorJohnson, Keith-
dc.contributor.authorSperling, Reisa-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorVisser, Denise-
dc.contributor.authorvan Berckel, Bart N M-
dc.contributor.authorvan der Flier, Wiesje M-
dc.contributor.authorBaker, Suzanne-
dc.contributor.authorJagust, William J-
dc.contributor.authorWiste, Heather J-
dc.contributor.authorPetersen, Ronald C-
dc.contributor.authorJack, Clifford R-
dc.contributor.authorHansson, Oskar-
dc.date2022-
dc.date.accessioned2023-01-12T02:52:53Z-
dc.date.available2023-01-12T02:52:53Z-
dc.date.issued2022-11-
dc.identifier.citationNature Medicine 2022en_US
dc.identifier.issn1546-170X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31754-
dc.description.abstractA major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET-positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the temporal neocortex (A+TNEO-T+) and compared them with A+T- and A-T- groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO-T+ (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9-33.7), A+TMTL+ (HR = 14.6, 95% CI = 8.1-26.4) and A+T- (HR = 2.4, 95% CI = 1.4-4.3) groups versus the A-T- (reference) group. Both A+TMTL+ (HR = 6.0, 95% CI = 3.4-10.6) and A+TNEO-T+ (HR = 7.9, 95% CI = 4.7-13.5) groups also showed faster clinical progression to mild cognitive impairment than the A+T- group. Linear mixed-effect models indicated that the A+TNEO-T+ (β = -0.056 ± 0.005, T = -11.55, P < 0.001), A+TMTL+ (β = -0.024 ± 0.005, T = -4.72, P < 0.001) and A+T- (β = -0.008 ± 0.002, T = -3.46, P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A-T- (reference) group (all P < 0.001). Both A+TNEO-T+ (P < 0.001) and A+TMTL+ (P = 0.002) groups also progressed faster than the A+T- group. In summary, evidence of advanced Alzheimer's disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.en_US
dc.language.isoeng-
dc.subjectAmyloiden_US
dc.subjecttau PET-positive cognitively unimpaireden_US
dc.titleAmyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNature Medicineen_US
dc.identifier.affiliationLund University, Clinical Memory Research Unit, Lund, Sweden.en_US
dc.identifier.affiliationDepartment of Radiation Physics, Skåne University Hospital, Lund, Sweden.en_US
dc.identifier.affiliationSkåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden.en_US
dc.identifier.affiliationDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.en_US
dc.identifier.affiliationThe Australian e-Health Research Centre CSIRO Melbourne Victoria Australia, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen_US
dc.identifier.affiliationMolecular Imaging and Therapyen_US
dc.identifier.affiliationAmsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.en_US
dc.identifier.affiliationAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.en_US
dc.identifier.affiliationLawrence Berkeley National Laboratory, Berkeley, CA, USA.en_US
dc.identifier.affiliationDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.en_US
dc.identifier.affiliationDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.en_US
dc.identifier.affiliationDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.en_US
dc.identifier.doi10.1038/s41591-022-02049-xen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-1584-7477en_US
dc.identifier.orcid0000-0001-5218-3337en_US
dc.identifier.orcid0000-0001-7147-0112en_US
dc.identifier.orcid0000-0002-9267-1930en_US
dc.identifier.orcid0000-0002-8051-0558en_US
dc.identifier.orcid0000-0002-5299-3628en_US
dc.identifier.orcid0000-0001-8766-6224en_US
dc.identifier.orcid0000-0002-4458-113Xen_US
dc.identifier.orcid0000-0002-8178-6601en_US
dc.identifier.orcid0000-0001-7916-622Xen_US
dc.identifier.orcid0000-0001-8467-7286en_US
dc.identifier.pubmedid36357681-
dc.description.volume28-
dc.description.issue11-
dc.description.startpage2381-
dc.description.endpage2387-
dc.subject.meshtermssecondaryAlzheimer Disease/pathology-
dc.subject.meshtermssecondarytau Proteins/metabolism-
dc.subject.meshtermssecondaryBrain/metabolism-
dc.subject.meshtermssecondaryCognitive Dysfunction/diagnostic imaging-
dc.subject.meshtermssecondaryPositron-Emission Tomography/methods-
dc.subject.meshtermssecondaryAmyloid/metabolism-
dc.subject.meshtermssecondaryAmyloid beta-Peptides/metabolism-
local.name.researcherDoré, Vincent
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Sep 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.